» Articles » PMID: 30759726

Targeting Immune Signaling Checkpoints in Acute Myeloid Leukemia

Overview
Journal J Clin Med
Specialty General Medicine
Date 2019 Feb 15
PMID 30759726
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

The modest successes of targeted therapies along with the curative effects of allogeneic hematopoietic stem cell transplantation (alloHSCT) in acute myeloid leukemia (AML) stimulate the development of new immunotherapies. One of the promising methods of immunotherapy is the activation of immune response by the targeting of negative control checkpoints. The two best-known inhibitory immune checkpoints are cytotoxic T-lymphocyte antigen-4 (CTLA-4) and the programmed cell death protein 1 receptor (PD-1). In AML, PD-1 expression is observed in T-cell subpopulations, including T regulatory lymphocytes. Increased PD-1 expression on CD8+ T lymphocytes may be one of the factors leading to dysfunction of cytotoxic T cells and inhibition of the immune response during the progressive course of AML. Upregulation of checkpoint molecules was observed after alloHSCT and therapy with hypomethylating agents, pointing to a potential clinical application in these settings. Encouraging results from recent clinical trials (a response rate above 50% in a relapsed setting) justify further clinical use. The most common clinical trials employ two PD-1 inhibitors (nivolumab and pembrolizumab) and two anti-PD-L1 (programmed death-ligand 1) monoclonal antibodies (atezolizumab and durvalumab). Several other inhibitors are under development or in early phases of clinical trials. The results of these clinical trials are awaited with great interest in, as they may allow for the established use of checkpoint inhibitors in the treatment of AML.

Citing Articles

Prospects for potential therapy targeting immune‑associated factors in endometriosis (Review).

Zhang W, Li K, Jian A, Zhang G, Zhang X Mol Med Rep. 2024; 31(3.

PMID: 39717957 PMC: 11715623. DOI: 10.3892/mmr.2024.13422.


Characterization of the Bone Marrow Lymphoid Microenvironment and Discovery of Prognostic Immune-Related Factors in Acute Myeloid Leukemia.

Kim Y, Kwag D, Kim B, Son H, Park S, Kim H Int J Mol Sci. 2024; 25(23).

PMID: 39684749 PMC: 11641137. DOI: 10.3390/ijms252313039.


A Review of Childhood Acute Myeloid Leukemia: Diagnosis and Novel Treatment.

Tseng S, Lee M, Lin P Pharmaceuticals (Basel). 2023; 16(11).

PMID: 38004478 PMC: 10674205. DOI: 10.3390/ph16111614.


Immunotherapy with Monoclonal Antibodies for Acute Myeloid Leukemia: A Work in Progress.

Molica M, Perrone S, Andriola C, Rossi M Cancers (Basel). 2023; 15(20).

PMID: 37894427 PMC: 10605302. DOI: 10.3390/cancers15205060.


Unveiling T cell evasion mechanisms to immune checkpoint inhibitors in acute myeloid leukemia.

Gurska L, Gritsman K Cancer Drug Resist. 2023; 6(3):674-687.

PMID: 37842238 PMC: 10571054. DOI: 10.20517/cdr.2023.39.


References
1.
Latchman Y, Wood C, Chernova T, Chaudhary D, Borde M, Chernova I . PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001; 2(3):261-8. DOI: 10.1038/85330. View

2.
Lee H, Park S, Choi B, Kim H, Nam K, Kwon B . 4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1. J Immunol. 2002; 169(9):4882-8. DOI: 10.4049/jimmunol.169.9.4882. View

3.
Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, Tanno Y . Expression of programmed death 1 ligands by murine T cells and APC. J Immunol. 2002; 169(10):5538-45. DOI: 10.4049/jimmunol.169.10.5538. View

4.
Ishida Y, Agata Y, Shibahara K, Honjo T . Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992; 11(11):3887-95. PMC: 556898. DOI: 10.1002/j.1460-2075.1992.tb05481.x. View

5.
Liang S, Latchman Y, Buhlmann J, Tomczak M, Horwitz B, Freeman G . Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol. 2003; 33(10):2706-16. DOI: 10.1002/eji.200324228. View